Literature DB >> 31018748

Anti-tumor activity and mechanism of oligoclonal hepatocellular carcinoma tumor-infiltrating lymphocytes in vivo and in vitro.

Wen-Chao Wang1,2, Zong-Qin Zhang1,3, Peng-Peng Li1, Jun-Yong Ma1, Lei Chen4, Hai-Hua Qian4, Le-Hua Shi4, Zheng-Feng Yin4, Bin Sun4, Xiao-Feng Zhang1.   

Abstract

Objective: To explore a method for culturing hepatocellular carcinoma and tumor-infiltrating lymphocytes (HCC-TIL) and investigate the mechanism of TIL in killing tumors.
Methods: The distribution of regulatory T cells (Treg) in HCC was detected by immunohistochemistry. Conventional TIL and oligoclonal TIL were isolated by the traditional method of enzyme digestion combined with mechanical treatment for whole HCC and micro HCC tissue block culturing method. MTT was used to compare the killing activity of TIL. Flow cytometry was used to analyze the proportion of CD8+ T cells and Treg cells in TIL. Tumor-bearing mice were established, and TIL adoptive immunotherapy was performed.
Results: Treg cells were mainly distributed in the stroma of HCC. In vitro experiments showed oligoclonal TIL had higher cytotoxicity to tumor cells which negatively correlated with the proportion of Treg cells. In vivo experiments showed oligoclonal TIL had a higher anti-tumor effect. IFN-γ in peripheral blood and the positive rate of intratumoral lymphocytic infiltration in oligoclonal TIL group were both higher. TGF-β and IL-10 in peripheral blood and the positive rate of intratumoral FoxP3 and IL-17 were both lower than those in conventional TIL group.
Conclusion: The oligoclonal TIL culture method could obtain TIL with higher purity, and cytotoxicity to tumor cells was associated with Treg cells. The oligoclonal TIL had cytotoxicity to autologous HCC cells and significant inhibitory effect on the growth of transplanted tumors. The mechanism might be associated with the inhibition of Treg cells proliferation, increase of IFN-γ secretion, and decrease of TGF-β, IL-10, and IL-17 secretion.

Entities:  

Keywords:  Anti-tumor activity; hepatocellular carcinoma; mechanism; oligoclone; tumor infiltrating lymphocytes

Year:  2019        PMID: 31018748      PMCID: PMC6741571          DOI: 10.1080/15384047.2019.1599663

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  24 in total

1.  Control of regulatory T cell development by the transcription factor Foxp3.

Authors:  Shohei Hori; Takashi Nomura; Shimon Sakaguchi
Journal:  Science       Date:  2003-01-09       Impact factor: 47.728

2.  T cell infiltration and prognosis in HCC patients.

Authors:  Giorgio Parmiani; Andrea Anichini
Journal:  J Hepatol       Date:  2006-06-15       Impact factor: 25.083

Review 3.  Regulatory T cells, tumour immunity and immunotherapy.

Authors:  Weiping Zou
Journal:  Nat Rev Immunol       Date:  2006-04       Impact factor: 53.106

4.  Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of T-regulatory cells.

Authors:  Esther Unitt; Simon M Rushbrook; Aileen Marshall; Susan Davies; Paul Gibbs; Lesley S Morris; Nicholas Coleman; Graeme J M Alexander
Journal:  Hepatology       Date:  2005-04       Impact factor: 17.425

5.  TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance.

Authors:  Dori A Thomas; Joan Massagué
Journal:  Cancer Cell       Date:  2005-11       Impact factor: 31.743

6.  Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity.

Authors:  J Shimizu; S Yamazaki; S Sakaguchi
Journal:  J Immunol       Date:  1999-11-15       Impact factor: 5.422

7.  Liver resection for metastatic melanoma with postoperative tumor-infiltrating lymphocyte therapy.

Authors:  R Taylor Ripley; Jeremy L Davis; Jacob A Klapper; Aarti Mathur; Udai Kammula; Richard E Royal; James C Yang; Richard M Sherry; Marybeth S Hughes; Steven K Libutti; Donald E White; Seth M Steinberg; Mark E Dudley; Steven A Rosenberg; Itzhak Avital
Journal:  Ann Surg Oncol       Date:  2009-09-24       Impact factor: 5.344

Review 8.  Regulatory T cells and treatment of cancer.

Authors:  Tyler J Curiel
Journal:  Curr Opin Immunol       Date:  2008-05-27       Impact factor: 7.486

9.  The immunosuppressive tumor microenvironment in hepatocellular carcinoma.

Authors:  Yan-Li Pang; Hua-Gang Zhang; Ji-Run Peng; Xue-Wen Pang; Shu Yu; Qiao Xing; Xin Yu; Lei Gong; Yan-Hui Yin; Yu Zhang; Wei-Feng Chen
Journal:  Cancer Immunol Immunother       Date:  2008-10-22       Impact factor: 6.968

Review 10.  Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma.

Authors:  Darryl A Oble; Robert Loewe; Ping Yu; Martin C Mihm
Journal:  Cancer Immun       Date:  2009-04-02
View more
  5 in total

Review 1.  Circular RNAs in the tumour microenvironment.

Authors:  Zhonghua Ma; You Shuai; Xiangyu Gao; Xianzi Wen; Jiafu Ji
Journal:  Mol Cancer       Date:  2020-01-14       Impact factor: 27.401

2.  SLC39A1 Overexpression is Associated with Immune Infiltration in Hepatocellular Carcinoma and Promotes Its Malignant Progression.

Authors:  Xiaowu Ma; Hongkai Zhuang; Qingbin Wang; Lei Yang; Zhiqin Xie; Ziyu Zhang; Wenliang Tan; Chenwei Tang; Yajin Chen; Changzhen Shang
Journal:  J Hepatocell Carcinoma       Date:  2022-02-15

3.  Changes in Inflammatory Markers Predict the Prognosis of Resected Hepatocellular Carcinoma with Child-Pugh A.

Authors:  Jing Zhou; Daofeng Yang
Journal:  Curr Oncol       Date:  2022-08-16       Impact factor: 3.109

Review 4.  Neoantigen vaccine: An emerging immunotherapy for hepatocellular carcinoma.

Authors:  Pu Chen; Qiong-Xuan Fang; Dong-Bo Chen; Hong-Song Chen
Journal:  World J Gastrointest Oncol       Date:  2021-07-15

5.  Neutrophil to lymphocyte and platelet to lymphocyte ratios as biomarkers to predict relapse and survival in posthepatectomy HBV-related hepatocellular carcinoma: a meta-analysis and preliminary immune perspective.

Authors:  Xia Zheng; Bin Ye; Yudong Gou; Zixiong Li; Chao Chen; Feng Liao; Xiufeng Liu; Shukui Qin
Journal:  Transl Cancer Res       Date:  2021-03       Impact factor: 1.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.